English  |  正體中文  |  简体中文  |  总笔数 :2853327  
造访人次 :  44987276    在线人数 :  1631
教育部委托研究计画      计画执行:国立台湾大学图书馆
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
关于TAIR

浏览

消息

著作权

相关连结

"tseng t c"的相关文件

回到依作者浏览
依题名排序 依日期排序

显示项目 291-340 / 534 (共11页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目

机构 日期 题名 作者
臺大學術典藏 2021-07-03T03:33:54Z Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study Su T.-H.;Liu C.-J.;Tseng T.-C.;Chou S.-W.;Liu C.-H.;Yang H.-C.;Wu S.-J.;Pei-Jer Chen;Chen D.-S.;Chen C.-L.;Kao J.-H.; Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; PEI-JER CHEN; Chen D.-S.; Chen C.-L.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:53Z Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection Yang W.-T.;Wu L.-W.;Tseng T.-C.;Chen C.-L.;Yang H.-C.;Su T.-H.;Wang C.-C.;Kuo S.F.-T.;Liu C.-H.;Pei-Jer Chen;Chen D.-S.;Liu C.-J.;Kao J.-H.; Yang W.-T.; Wu L.-W.; Tseng T.-C.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Liu C.-J.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:52Z Perspectives on dual hepatitis B and C infection in Taiwan Liu C.-J.;Pei-Jer Chen;Chen D.-S.;Tseng T.-C.;Kao J.-H.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Tseng T.-C.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:50Z Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C Mah Y.-H.;Liu C.-H.;Chen C.-L.;Tseng T.-C.;Liu C.-J.;Pei-Jer Chen;Chen D.-S.;Kao J.-H.; Mah Y.-H.; Liu C.-H.; Chen C.-L.; Tseng T.-C.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:46Z Fibrosis-4 Index Helps Identify HBV Carriers with the Lowest Risk of Hepatocellular Carcinoma Tseng T.-C.; Liu C.-J.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:46Z Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up Chen H.-Y.; Su T.-H.; Tseng T.-C.; Yang W.-T.; Chen T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.; Liu C.-J.
臺大學術典藏 2021-07-03T03:33:43Z Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis Su T.-H.; Shiau C.-W.; Jao P.; Yang N.-J.; Tai W.-T.; Liu C.-J.; Tseng T.-C.; Yang H.-C.; Liu C.-H.; Huang K.-W.; Hu T.-C.; Huang Y.-J.; Wu Y.-M.; Chen L.-J.; PEI-JER CHEN; Chen D.-S.; Chen K.-F.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:40Z Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:39Z Distinct Relapse Rates and Risk Predictors after Discontinuing Tenofovir and Entecavir Therapy Su T.-H.; Yang H.-C.; Tseng T.-C.; Liou J.-M.; Liu C.-H.; Chen C.-L.; PEI-JER CHEN; Chen D.-S.; Liu C.-J.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:38Z Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection Liu C.-H.; Sun H.-Y.; Liu C.-J.; Sheng W.-H.; Hsieh S.-M.; Lo Y.-C.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Hung C.-C.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:38Z Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection Tseng T.-C.; Liu C.-J.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Kuo S.F.-T.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:37Z Acoustic radiation force impulse US imaging: Liver stiffness in patients with chronic hepatitis B with and without antiviral therapy Su T.-H.; Liao C.-H.; Liu C.-H.; Huang K.-W.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:36Z Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Hung C.-C.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:35Z Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:34Z Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection Su T.-H.;Liu C.-J.;Tseng T.-C.;Chou S.-W.;Liu C.-H.;Yang H.-C.;Wu S.-J.;Pei-Jer Chen;Chen D.-S.;Chen C.-L.;Kao J.-H.; Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; PEI-JER CHEN; Chen D.-S.; Chen C.-L.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:34Z Profile and value of FIB-4 in patients with dual chronic hepatitis C and B Liu C.-J.;Tseng T.-C.;Yang W.-T.;Su T.-H.;Yang H.-C.;Liu C.-H.;Pei-Jer Chen;Chen D.-S.;Kao J.-H.; Liu C.-J.; Tseng T.-C.; Yang W.-T.; Su T.-H.; Yang H.-C.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:33Z Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma Su T.-H.;Liu C.-J.;Tseng T.-C.;Chou S.-W.;Liu C.-H.;Yang H.-C.;Wu S.-J.;Pei-Jer Chen;Chen D.-S.;Chen C.-L.;Kao J.-H.; Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; PEI-JER CHEN; Chen D.-S.; Chen C.-L.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:32Z Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection Liu C.-H.;Su T.-H.;Liu C.-J.;Hong C.-M.;Yang H.-C.;Tseng T.-C.;Pei-Jer Chen;Chen D.-S.;Kao J.-H.; Liu C.-H.; Su T.-H.; Liu C.-J.; Hong C.-M.; Yang H.-C.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:31Z NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging Su T.-H.;Liao S.-H.;Hong C.-M.;Liu C.-J.;Tseng T.-C.;Liu C.-H.;Yang H.-C.;Pei-Jer Chen;Chen D.-S.;Chen C.-L.;Adhoute X.;Bourli?Re M.;Kao J.-H.; Su T.-H.; Liao S.-H.; Hong C.-M.; Liu C.-J.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chen C.-L.; Adhoute X.; Bourli?re M.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:29Z High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load Tseng T.-C.;Liu C.-J.;Hsu C.-Y.;Hong C.-M.;Su T.-H.;Yang W.-T.;Chen C.-L.;Yang H.-C.;Huang Y.-T.;Fang-Tzu Kuo S.;Liu C.-H.;Pei-Jer Chen;Chen D.-S.;Kao J.-H.; Tseng T.-C.; Liu C.-J.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Huang Y.-T.; Fang-Tzu Kuo S.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:28Z Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis Su T.-H.; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; Liu C.-J.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:27Z Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:27Z Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan Liu C.-H.; Liu C.-J.; Hung C.-C.; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:26Z HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis Tseng T.-C.; Liu C.-J.; Chang C.T.; Su T.-H.; Yang W.-T.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:26Z Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; Liu C.-J.; Su T.-H.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:26Z Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals Liu C.-H.; Lee M.-H.; Lin J.-W.; Liu C.-J.; Su T.-H.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:23Z Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer Su T.-H.; Tseng T.-C.; Liu C.-J.; Chou S.-W.; Liu C.-H.; Yang H.-C.; PEI-JER CHEN; Chen D.-S.; Chen C.-L.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:22Z Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan Su H.-J.; Kao J.-H.; Tseng T.-C.; Yang H.-C.; Su T.-H.; PEI-JER CHEN; Liu C.-J.
臺大學術典藏 2021-07-03T03:33:21Z High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu C.-H.; PEI-JER CHEN; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-07-03T03:33:17Z Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load Tseng T.-C.; Liu C.-J.; Yang W.-T.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; PEI-JER CHEN; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:15Z Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:14Z Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:14Z Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection Liu C.-H.; Sun H.-Y.; Liu C.-J.; Sheng W.-H.; Hsieh S.-M.; Lo Y.-C.; Liu W.-C.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:13Z Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection Liu C.-H.; Su T.-H.; Liu C.-J.; CHUN-MING HONG; Yang H.-C.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:13Z Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:13Z NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging Su T.-H.; Liao S.-H.; CHUN-MING HONG; Liu C.-J.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Adhoute X.; Bourlière M.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:12Z High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load Tseng T.-C.; Liu C.-J.; Hsu C.-Y.; CHUN-MING HONG; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Huang Y.-T.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-06-25T08:10:11Z Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load Tseng T.-C.; Liu C.-J.; Yang W.-T.; Hsu C.-Y.; CHUN-MING HONG; Su T.-H.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; Chen P.-J.; Kao J.-H.
臺大學術典藏 2021-06-03T06:50:15Z Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition Su T.-H.;Shiau C.-W.;Jao P.;Liu C.-H.;Liu C.-J.;Tai W.-T.;Jeng Y.-M.;Yang H.-C.;Tseng T.-C.;Hsiang-Po Huang;Cheng H.-R.;Chen P.-J.;Chen K.-F.;Kao J.-H.;Chen D.-S.; Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; HSIANG-PO HUANG; Cheng H.-R.; Chen P.-J.; Chen K.-F.; Kao J.-H.; Chen D.-S.
臺大學術典藏 2021-05-27T08:20:46Z Distinct Relapse Rates and Risk Predictors after Discontinuing Tenofovir and Entecavir Therapy Su T.-H.; Yang H.-C.; Tseng T.-C.; JYH-MING LIOU; Liu C.-H.; Chen C.-L.; Chen P.-J.; Chen D.-S.; Liu C.-J.; Kao J.-H.
臺大學術典藏 2021-05-24T07:20:53Z Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial CHEN-HUA LIU; Liu C.-J.; Lin C.-.; Liang C.-C.; Hsu S.-J.; Yang S.-S.; Hsu C.-S.; Tseng T.-C.; Wang C.-C.; Lai M.-Y.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-05-24T07:20:51Z Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B Su T.-H.; Hsu C.-S.; Chen C.-L.; CHEN-HUA LIU; Huang Y.-W.; Tseng T.-C.; Liu C.-J.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-05-24T07:20:49Z Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: Genotype B vs C Liu C.-J.; Cheng H.-R.; Chen C.-L.; Chen T.-C.; Tseng T.-C.; Wang Z.-L.; Chen P.-J.; CHEN-HUA LIU; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-05-24T07:20:49Z Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy Tseng T.-C.; Yu M.-L.; Liu C.-J.; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; CHEN-HUA LIU; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-05-24T07:20:47Z Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy Hsu C.-S.; Hsu S.-J.; Chen H.-C.; Tseng T.-C.; CHEN-HUA LIU; Niu W.-F.; Jeng J.; Liu C.-J.; Lai M.-Y.; Chen P.-J.; Kao J.-H.; Chen D.-S.
臺大學術典藏 2021-05-24T07:20:46Z Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load Tseng T.-C.; Liu C.-J.; Yang H.-C.; Su T.-H.; Wang C.-C.; Chen C.-L.; Fang-Tzu Kuo S.; CHEN-HUA LIU; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-05-24T07:20:46Z High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load Tseng T.-C.; Liu C.-J.; Yang H.-C.; Su T.-H.; Wang C.-C.; Chen C.-L.; Kuo S.F.-T.; CHEN-HUA LIU; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-05-24T07:20:46Z Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin CHEN-HUA LIU; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-05-24T07:20:46Z Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy CHEN-HUA LIU; Liang C.-C.; Liu C.-J.; Tseng T.-C.; Lin C.-L.; Yang S.-S.; Su T.-H.; Hsu S.-J.; Lin J.-W.; Chen J.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏 2021-05-24T07:20:45Z Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B Pan C.J.-H.; Wu H.-L.; Kuo S.F.-T.; Kao J.-H.; Tseng T.-C.; CHEN-HUA LIU; Chen P.-J.; Liu C.-J.; Chen D.-S.

显示项目 291-340 / 534 (共11页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目